ImmunoPrecise Antibodies Ltd. (IPA)

NASDAQ: IPA · IEX Real-Time Price · USD
1.97
-0.10 (-4.83%)
At close: Sep 22, 2023, 4:00 PM
1.90
-0.07 (-3.55%)
After-hours: Sep 22, 2023, 4:05 PM EDT
-4.83%
Market Cap 49.35M
Revenue (ttm) 16.41M
Net Income (ttm) -15.72M
Shares Out 25.05M
EPS (ttm) -0.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 27,489
Open 2.05
Previous Close 2.07
Day's Range 1.96 - 2.14
52-Week Range 1.70 - 5.90
Beta 0.50
Analysts Strong Buy
Price Target 8.00 (+306.09%)
Earnings Date Sep 14, 2023

About IPA

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In a... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 3, 2017
Employees 102
Stock Exchange NASDAQ
Ticker Symbol IPA
Full Company Profile

Financial Performance

In 2023, IPA's revenue was 20.67 million, an increase of 6.72% compared to the previous year's 19.36 million. Losses were -26.56 million, 59.0% more than in 2022.

Financial numbers in CAD Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for IPA stock is "Strong Buy." The 12-month stock price forecast is $8.0, which is an increase of 306.09% from the latest price.

Price Target
$8.0
(306.09% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

ImmunoPrecise Antibodies Announces CFO Transition

VICTORIA, British Columbia--(BUSINESS WIRE)--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), today announced that it has accepted the resignation of Brad McConn, CFO, effec...

4 days ago - Business Wire

IPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024

VICTORIA, British Columbia--(BUSINESS WIRE)--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced fi...

9 days ago - Business Wire

IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024 on September 14, 2023

VICTORIA, British Columbia--(BUSINESS WIRE)--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced tha...

15 days ago - Business Wire

IPA Announces Board Refreshment

VICTORIA, British Columbia--(BUSINESS WIRE)--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, is pleased to annou...

18 days ago - Business Wire

IPA Responds to 13D Filing

VICTORIA, British Columbia--(BUSINESS WIRE)--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today issued the fo...

6 weeks ago - Business Wire

ImmunoPrecise Antibodies Invites Investors and Stakeholders to Exclusive Interview with Market Radius Research

VICTORIA, British Columbia--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA" or the "Company"), an AI-driven biotherapeutic research and technology, is delighted to extend an invita...

2 months ago - Business Wire

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2023

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today...

2 months ago - Business Wire

IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2023 on July 7th, 2023.

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), a leader in AI-driven biotherapeutic research and technology, toda...

3 months ago - Business Wire

IPA's Subsidiary BioStrand Unveils Use Case for Solving the Information Integration Dilemma (IID)

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, is excited...

3 months ago - Business Wire

IPA Releases New HYFT-Powered In Silico Humanization Platform, Aims to Disrupt the Transgenic Animal Model Market

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”) today introduced a transformative AI-driven rapid therapeutic screening p...

3 months ago - Business Wire

IPA's Subsidiary, BioStrand, Solves the Information Integration Dilemma (IID) for Systems Biology

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), an AI-driven biotherapeutic research and technology c...

4 months ago - Business Wire

IPA to Present at Jefferies Healthcare Conference 2023

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”) an AI-driven biotherapeutic research and technology co...

4 months ago - Business Wire

ImmunoPrecise's Subsidiary Talem Enters into Exclusive Research Collaboration and License Option Agreement with Astellas

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”) an AI-driven biotherapeutic research and technology co...

6 months ago - Business Wire

European Patent Office to Grant BioKey's Patent Application for Foundational HYFT® Technology

VICTORIA, British Colombia--(BUSINESS WIRE)---- $IPA #AI--Immunoprecise Antibodies Ltd. (NASDAQ: IPA) (“Immunoprecise” or “IPA” or the “Company”), the parent company of BioKey and affiliate of BioStra...

6 months ago - Business Wire

ImmunoPrecise Presents Novel T-Cell Engaging Bispecific Antibodies Addressing a Unique Oncological Target, Tropomyosin Receptor Kinase B, Associated with Poor Prognosis and Survival Rates

VICTORIA, British Colombia--(BUSINESS WIRE)---- $IPA #AI--Immunoprecise Antibodies Ltd. (NASDAQ: IPA) (“Immunoprecise” or “IPA” or the “Company”), an AI-driven biotherapeutic research and technology c...

6 months ago - Business Wire

IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2023

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today...

6 months ago - Business Wire

ImmunoPrecise Antibodies' Subsidiary Talem Therapeutics Announces a Multi-Target AI-Driven Antibody Discovery Collaboration with Libera Bio

VICTORIA, British Columbia & SANTIAGO DE COMPOSTELA, Spain--(BUSINESS WIRE)---- $IPA #AI--Immunoprecise Antibodies Ltd. (NASDAQ: IPA) (“Immunoprecise” or “IPA” or the “Company”), an AI-driven biothera...

6 months ago - Business Wire

IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2023 on March 16, 2023

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today ...

7 months ago - Business Wire

IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023

VICTORIA, British Columbia--(BUSINESS WIRE)--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced ...

10 months ago - Business Wire

IPA's Subsidiary BioStrand Completes Integration of 20 Million Proprietary Structural HYFTs™ and Accelerates in Silico Drug Discovery Developments

VICTORIA, British Columbia--(BUSINESS WIRE)--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced t...

10 months ago - Business Wire

IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023 on December 15, 2022

VICTORIA, British Columbia--(BUSINESS WIRE)--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced t...

10 months ago - Business Wire

IPA's Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies

VICTORIA, British Columbia & VANCOUVER, British Columbia & PHILADELPHIA--(BUSINESS WIRE)--IPA (IMMUNOPRECISE ANTIBODIES LTD.) ( “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technolo...

Other symbols: BCTX
10 months ago - Business Wire

ImmunoPrecise Antibodies Ltd. Announces Voluntary Delisting from TSX Venture Exchange

VICTORIA, British Columbia--(BUSINESS WIRE)--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA) announces that it has applied and has received approval for a volu...

10 months ago - Business Wire

IPA's Subsidiary Talem Therapeutics Licenses Antibodies for Three OmniChicken-Derived Programs

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.

1 year ago - Business Wire

NIAID Confirms IPA's PolyTope TATX-03 Neutralizing Activity Against the Currently Spreading SARS-CoV-2 Variant BA.2.75

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), announced today that its subsidiary, Talem Therapeutic...

1 year ago - Business Wire